CTOs on the Move

Maxygen, Inc.

www.maxygen.com

 
Maxygen, Inc. (Maxygen) is a biotechnology company engaged in the discovery and development of improved protein pharmaceuticals for the treatment of disease and serious medical conditions.
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.maxygen.com
  • 515 Galveston Dr
    Redwood City, CA USA 94063-4720
  • Phone: 650.298.5300

Executives

Name Title Contact Details

Similar Companies

Disaster Management Group

Disaster Management Group, LLC is a Stuart, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Volpara Health

Volpara Health provides an advanced AI software platform that enables a high-quality, optimized and personalized cancer screening experience. From the time a patient enters a clinic to the moment they obtain key results, the Volpara Breast Health Platform collects and analyzes information to better understand a patient`s breast cancer risk, while also objectively evaluating image quality and workflow-improvement opportunities. More than thirteen million women across 39 countries have had their breast density assessed by Volpara. The company`s software is installed in approximately 2000 leading facilities worldwide, including top cancer centers in the United States. Volpara Health`s technology has been the subject of more than 300 publications. The Volpara Breast Health Platform is supported by numerous patents, trademarks, and regulatory registrations, including FDA clearance and CE marking.

Parkview Adventist Medical Center

Parkview Adventist Medical Center is a Brunswick, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.

Executive Source International

Executive Source International is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.